(53 days)
No
The summary describes standard ultrasound imaging and image processing techniques, with no mention of AI or ML. The performance study focuses on the qualitative assessment of tissue stiffness based on the generated images, not on an automated AI/ML-based analysis.
No
The device is an imaging system designed for diagnostic purposes (B-mode ultrasonic imaging to determine if a region of interest is harder or softer than the surrounding tissue), not for treating conditions.
Yes
The device is indicated for B-mode ultrasonic imaging and generates relative stiffness ultrasound images of the breast, which are used to determine if a region of interest is harder or softer than the surrounding tissue. This information aids in the characterization of breast tissue, which is a diagnostic function even if "no clinical diagnostic claims are being made" for the new stiffness feature. The output images are stored for review by a radiologist.
No
The device description explicitly lists multiple hardware subsystems including a Transducer, Table/Housing Assembly, Water Conditioning System, Computer Control System, Power System, and Data Acquisition System. It also describes physical components like a curvilinear transducer, table, imaging chamber, camera, barcode reader, and touchscreen display. This indicates it is a hardware-based medical device with integrated software, not a software-only device.
Based on the provided information, the SoftVue™ device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs are used to examine specimens derived from the human body. The SoftVue™ device directly images the patient's breast using ultrasound. It does not analyze blood, tissue samples, or other bodily fluids or materials.
- The intended use is for B-mode ultrasonic imaging of the breast. This is an in-vivo imaging technique, not an in-vitro diagnostic test.
- The device description details an imaging system. It describes a transducer, table, water system, computer control, and image reconstruction, all components of an imaging device.
- The performance studies involve imaging patients and phantoms. This further supports its use as an imaging system rather than an IVD.
While the device provides information about the relative stiffness of tissue, which could be used to aid in diagnosis, the mechanism of action is through ultrasound imaging of the living tissue, not through the analysis of a specimen outside the body.
N/A
Intended Use / Indications for Use
SoftVue™ is indicated for use as a B-mode ultrasonic imaging of a patient's breast when used with an automatic scanning curvilinear array transducer. The device is not intended to be used as a replacement for screening mammography.
Product codes (comma separated list FDA assigned to the subject device)
IYO, ITX
Device Description
SoftVue™ is comprised of the following subsystems: the Transducer, Table/Housing Assembly, Water Conditioning System, Computer Control System, Image Reconstruction System, Power System, and the Data Acquisition System.
Soft Vue™ has a built-in curvilinear transducer that is used to acquire ultrasound data. Data are acquired from a patient lying prone on the table with their breast submerged in an imaging chamber filled with warm (body temperature) water. The breast is positioned in the center of the transducer. A camera, located at the bottom of the imaging chamber provides a live video feed to the system operator to aid in positioning the patient's breast. Once the scan is initiated, the transducer collects data that are processed to produce a series of B-mode ultrasound image slices that can be stacked to yield a volumetric ultrasound image of the breast. Soft Vue™ also outputs colorized and grayscale relative stiffness image stacks that provide the radiologist with additional reference information.
The Water Control System is used to de-gas and warm the water that is used as the image acquisition medium. The Computer Control System controls all of the functionality of the other subsystems. The reconstruction engine processes the image data acquired by the transducer ring into B-mode ultrasound images.
The system includes a barcode reader and a touchscreen display (user interface). The touchscreen display allows the user to perform an imaging procedure. Patient information is entered into the system using either the QWERTY keyboard on the touchscreen display, using the barcode reader, or the user can import the patient information from a DICOM modality worklist on an externally networked RIS server. Device errors and warnings are displayed on the touchscreen display.
SoftVue™ outputs the images to an externally networked PACS server which allows the images to be stored until they are reviewed on a workstation.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Ultrasonic pulsed echo imaging system
Anatomical Site
Breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A small scale clinical study was conducted.
Sample Size: 10 SoftVue patient exams, consisting of 13 imaged masses (4 cancers, 4 fibroadenomas, and 5 cysts).
Data Source: Clinical study data collected from a modified SoftVue system installed at the Alexander J Walt Breast Center at the Karmanos Cancer Institute in Detroit, Michigan, as part of a clinical study under pre-IED # I120143.
Annotation Protocol: Not explicitly detailed as an annotation protocol, but patient data were chosen based on suspicion or biopsy-proven lesions and identified by appearance (echogenicity), size (dimensions), and location (clock position). Images were reviewed by a board-certified radiologist, Dr. Peter Littrup, using previous biopsies and/or imaging for guidance.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Study Type: Non-clinical design verification and validation testing, system performance and simulated use tests, acoustic output testing, safety testing, image characterization testing using clinical data, phantom analysis, small scale clinical study.
Sample Size: For clinical image characterization, 10-20 patients were suggested, with a range of breast densities, small to large breasts, and lesion sizes 5 mm to 15 mm or 20 mm. The actual clinical study used 10 SoftVue patient exams, which included 13 imaged masses.
AUC: Not Found
MRMC: Not Found
Standalone Performance: Not Found
Key Results:
- Phantom analysis: Demonstrated SoftVue's ability to provide qualitative tissue stiffness information. 7 phantom inclusions were imaged; 1 cancer and 3 fibroadenomas were stiff (red), and 3 cysts were soft (blue), correlating with known properties.
- Clinical image analysis: 10 SoftVue patient exams (13 masses total: 4 cancers, 4 fibroadenomas, 5 cysts).
- All 4 cancers were characterized as "stiff" by SoftVue's color stiffness images.
- Two fibroadenomas were mixed, 1 was stiff, and 1 was soft.
- Of the 5 cysts, 4 were soft, while 1 was mixed.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1560 Ultrasonic pulsed echo imaging system.
(a)
Identification. An ultrasonic pulsed echo imaging system is a device intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). A biopsy needle guide kit intended for use with an ultrasonic pulsed echo imaging system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services - USA. The logo features a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol consisting of three overlapping human profiles facing to the right, with flowing lines extending from the bottom of the profiles.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 31, 2014
Delphinus Medical Technologies, Inc. % Ms. Andrea Wallen-Gerding Director of Quality & Regulatory Affairs 46701 Commerce Center Drive PLYMOUTH MI 48170
Re: K142517
Trade/Device Name: SoftVue Regulation Number: 21 CFR 892.1560 Regulation Name: Ultrasonic pulsed echo imaging system Regulatory Class: II Product Code: IYO, ITX Dated: September 10, 2014 Received: September 11, 2014
Dear Ms. Wallen-Gerding:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Smh.7)
for
Janine M. Morris Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name SoftVue
Indications for Use (Describe)
SoftVue™ is indicated for use as a B-mode ultrasonic imaging of a patient's breast when used with an automatic scanning curvilinear array transducer. The device is not intended to be used as a replacement for screening mammography.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Diagnostic Ultrasound Indications for Use
System: SoftVue
| Clinical Application | Mode of Operation | |||||||
|---|---|---|---|---|---|---|---|---|
| General | ||||||||
| (Track 1 Only) | Specific | |||||||
| (Tracks 1 & 3) | B | M | PWD | CWD | Color | |||
| Doppler | Combined | |||||||
| (Specify) | Other* | |||||||
| (Specify) | ||||||||
| Ophthalmic | Ophthalmic | |||||||
| Fetal Imaging & | ||||||||
| Other | Fetal | |||||||
| Abdominal | ||||||||
| Intra-operative (Specify) | ||||||||
| Intra-operative (Neuro) | ||||||||
| Laparoscopic | ||||||||
| Pediatric | ||||||||
| Small Organ (Breast) | P | |||||||
| Neonatal Cephalic | ||||||||
| Adult Cephalic | ||||||||
| Trans-rectal | ||||||||
| Trans-vaginal | ||||||||
| Trans-urethral | ||||||||
| Trans-esoph. (non-Card.) | ||||||||
| Musculo-skeletal (Conventional) | ||||||||
| Musculo-skeletal (Superficial) | ||||||||
| Intravascular | ||||||||
| Other (Specify) | ||||||||
| Cardiac | Cardiac Adult | |||||||
| Cardiac Pediatric | ||||||||
| Intravascular (Cardiac) | ||||||||
| Trans-esoph. (Cardiac) | ||||||||
| Intra-cardiac | ||||||||
| Other (Specify) | ||||||||
| Peripheral | ||||||||
| Vessel | Peripheral vessel | |||||||
| Other (Specify) |
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N = new indication; P = previously cleared by FDA; E = added under this appendix
Additional Comments: SoftVue is intended for ultrasonic breast examinations
4
1.0 Submitter Information
-
1.1 This Premarket Notification is submitted by:
Delphinus Medical Technologies, Inc. 46701 commerce Center Drive Plymouth, Michigan 48170 -
1.2 Contact Information:
Contact Name: Andrea N. Wallen-Gerding 734-233-3984 Office Telephone: Fax: 734-207-3165 E-mail: awallen@delphinusmt.com -
1.3 Date: September 5, 2014
2.0 Device Name
- Trade/ Proprietary Name: SoftVue 2.1
- 2.2 Common Name:
- System, Imaging, Pulsed Echo Ultrasonic A
- A Transducer, Ultrasonic, Diagnostic
- Classification Name: 2.3
- 21 CFR § 892.1560: Ultrasonic pulsed echo imaging system A
- 21 CFR § 892-1570: Diagnostic ultrasonic transducer A
3.0 Predicate Device
The predicate device is identified as SoftVue™ manufactured by Delphinus Medical Technologies. SoftVue™ received market clearance under 510(k) number K123209.
The Toshiba Aplio 500 (K133761) was used as a secondary predicate device for elastography image comparison.
4.0 Device Description
SoftVue™ is indicated for use as a B-mode ultrasonic imaging system for imaging of a patient's breast using a curvilinear array transducer that completely surrounds the breast. The modification of SoftVue™ will allow the system to generate colorized and grayscale relative stiffness ultrasound images in addition to the grayscale B-mode images generated by the unmodified SoftVue™ system. This new feature will allow the user to be able to determine
5
whether a region of interest is harder or softer than the surrounding tissue. No clinical diagnostic claims are being made.
SoftVue™ is comprised of the following subsystems: the Transducer, Table/Housing Assembly, Water Conditioning System, Computer Control System, Image Reconstruction System, Power System, and the Data Acquisition System.
Soft Vue™ has a built-in curvilinear transducer that is used to acquire ultrasound data. Data are acquired from a patient lying prone on the table with their breast submerged in an imaging chamber filled with warm (body temperature) water. The breast is positioned in the center of the transducer. A camera, located at the bottom of the imaging chamber provides a live video feed to the system operator to aid in positioning the patient's breast. Once the scan is initiated, the transducer collects data that are processed to produce a series of B-mode ultrasound image slices that can be stacked to yield a volumetric ultrasound image of the breast. Soft Vue™ also outputs colorized and grayscale relative stiffness image stacks that provide the radiologist with additional reference information.
The Water Control System is used to de-gas and warm the water that is used as the image acquisition medium. The Computer Control System controls all of the functionality of the other subsystems. The reconstruction engine processes the image data acquired by the transducer ring into B-mode ultrasound images.
The system includes a barcode reader and a touchscreen display (user interface). The touchscreen display allows the user to perform an imaging procedure. Patient information is entered into the system using either the QWERTY keyboard on the touchscreen display, using the barcode reader, or the user can import the patient information from a DICOM modality worklist on an externally networked RIS server. Device errors and warnings are displayed on the touchscreen display.
SoftVue™ outputs the images to an externally networked PACS server which allows the images to be stored until they are reviewed on a workstation.
Intended Use 5.0
SoftVue™ is indicated for use as a B-mode ultrasonic imaging system for imaging of a patient's breast when used with an automatic scanning curvilinear array transducer. The device is not intended to be used as a replacement for screening mammography.
Predicate Device Comparison 6.0
Delphinus Medical Technologies claims that the SoftVue device is substantially equivalent to the SoftVue system cleared by the FDA in K123209. Delphinus Medical Technologies claims substantial equivalence because the proposed device has an equivalent intended use, manufacturing materials, operating principles, physical and operational specifications as compared to the predicate device.
6
The SoftVue device and the predicate device utilize B-mode grayscale ultrasound images to achieve their intended use. Both the modified SoftVue device and the unmodified predicate SoftVue device are table-top systems that have automatic scanning transducers to image breast tissue.
The specific details regarding similarities and differences between the modified SoftVue device and the unmodified SoftVue device have been identified and explained in the Comparison Table section provided in Section 10 of this submission. A brief summary of the similarities and differences between the modified SoftVue device and the unmodified SoftVue device is included below. The differences noted between the modified SoftVue device and the unmodified SoftVue device do not present any new issues related to safety and effectiveness.
Similarities:
- The modified and unmodified SoftVue devices use an automated transducer to acquire A 2D images of a patient's breast.
- A The modified and unmodified SoftVue devices use broadband transducers.
- A The modified and unmodified SoftVue devices have a single operating frequency of 3 MHz.
- A Both systems acquire and process B-mode grayscale images of a patient's breast.
- Both systems position the patient in a prone position lying on their examination table A with the patient's in a pendulous position within an imaging chamber.
- A Both systems position the patient's breast in a fluid environment to eliminate the need for breast compression and facilitate the transmission of ultrasound waves.
Differences:
- A The differences between the modified and unmodified Soft Vue systems are listed in Table 1 below.
| Item # | Modification | Reason for Change |
|---|---|---|
| 1 | Added mesh to the spillage chamber. | Prevent debris from entering/ getting trapped and |
| degrading valves. | ||
| 2 | Added a second membrane module | |
| to degasser | Improve degassing efficiency and maintain the | |
| same flow rate of water. | ||
| 3 | Replaced transmit power supplies | |
| with medical grade power supplies | Conform to 60601-1:2005 | |
| 4 | Replaced in-line filter with medical | |
| grade version | Conform to 60601-1:2005 | |
| 5 | Added Ethernet opto-isolator | Conform to 60601-1:2005 |
| 6 | Replaced vacuum pump circuit | |
| breaker with lower amp circuit | ||
| breaker | Conform to 60601-1:2005 | |
| 7 | Added thermistor interface board | Better match reservoir and imaging chamber |
Table 1: Changes made to Modified SoftVue System
7
| Item # | Modification | Reason for Change |
|---|---|---|
| 8 | Added cleaning tools | temperature sensors to more practical values |
| 9 | Parallelized user login and system initialization | Allows the user to view the status of the initialization process. |
| 10 | Added ability to query external RIS server | Allows user to upload patient information for an exam. |
| 11 | Updated GUI | Updated to accommodate other changes made such as allowing research users to select between running a research or clinical exam, RIS query, and initialization status. |
| 12 | Added acquisition PCBA temperature monitoring | Safety feature |
| 13 | Transferred full control of motors to control computer | Streamline system operation |
| 14 | Added ability to generate and output color and grayscale relative stiffness images | Additional reference information for radiologists |
| 15 | Improved image quality by updating pre-processing of attenuation image (not displayed) and updating sound speed image parameters. | Improve image quality. |
| • Updates to the pre-processing of the attenuation image result in better gain correction and equivalent contrast for the B-mode image. | ||
| • Updates to the sound speed image parameters results in better delay correction and equivalent contrast for the B-mode image. | ||
| 16 | Fixed a bug in firmware on the digital image processing board | Improve acquisition reliability |
| 17 | Updated the Master Clock and PCIe Interface (MCP) Board to make clock signals more reliable | Improve initialization reliability |
7.0 Summary of Non-Clinical Testing
- 7.1 The function and performance of the modified SoftVue device has been evaluated through non-clinical design verification and validation testing. Testing includes system performance and simulated use tests. The results of the evaluation tests demonstrate that the modified SoftVue device successfully meets the requirements of its intended use.
- 7.2 Delphinus Medical Technologies conducted performance evaluations to verify that SoftVue's subsystems successfully meet predetermined specifications and product performance requirements. Results of the testing performed demonstrate that SoftVue's subsystems meet the system and performance requirements necessary for its intended use. A brief list of some of the testing performed is included below.
- 7.2.1 Software Unit and System Verification and Validation Testing - Software was tested at the unit and system level to ensure that it met the software's design and
8
intended use requirements. All requirements were met and no new issues of safety or effectiveness were raised.
- 7.2.2 Sub-system Verification Testing - SoftVue subsystems that were modified from the original SoftVue system that received clearance to market underwent subsystem verification to ensure that they met their respective design requirements. All requirements were met and no new issues of safety or effectiveness were raised.
- 7.2.3 System Verification Testing - Since there were modifications made to the SoftVue system as a whole, system verification testing was conducted to ensure that the modified SoftVue system met the design requirements. All requirements were met and no new issues of safety or effectiveness were raised.
- 7.2.4 Human Factors/Usability Testing: Usability testing was conducted per the FDA Guidelines and ANSI/AAMI HE75:2009. All requirements were met and no new issues of safety or effectiveness were raised.
- 7.2.5 Design Validation Testing - Testing was conducted to ensure that the modified SoftVue device met the user needs and intended use requirements. All requirements were met and no new issues of safety or effectiveness were raised.
- 7.3 Soft Vue has undergone acoustic output testing per IEC 60601-2-37:2007. Testing was conducted by Acertara Acoustic Laboratories, an independent testing laboratory, located in Longmont, Colorado. SoftVue meets all Track 1 acoustic output requirements. The results of acoustic output testing are listed in Table 2 below. A copy of the test report can be found in Appendix 09-E of Section 9 (Declaration of Conformity) of this submission.
| Feature | Track 1 Exposure Level | SoftVue Level | Pass/Fail |
|---|---|---|---|
| Max. Mechanical Index | |||
| (MI) | 1.9 | 0.431 | Pass |
| Max. ISPTA.3 | 94 mW/cm2 | 15.1 mW/cm2 | Pass |
| Max. Soft Tissue Thermal | |||
| Index (TIS) | 0.0006 |
Table 2: Global Maximum Acoustic Output Values
- 7.4 In addition to the tests listed above, the modified SoftVue device has also undergone testing to the safety standards listed in Table 3 below.
| Table 3: Safety Testing Performed on SoftVue | ||||||
|---|---|---|---|---|---|---|
| ---------------------------------------------- | -- | -- | -- | -- | -- | -- |
| Standard # and Date | Standard Title |
|---|---|
| IEC 60601-1:2005; Corr. | |
| 1:2006; Corr. 2:2007 | Medical Electrical Equipment - Part 1: General Requirements for Safety, 1988; |
| Amendment 1, 1991-11, Amendment 2, 1995 | |
| IEC 60601-1-2:2007 | Medical Electrical Equipment - Part 1-2: General Requirements for Safety - |
| Collateral standard: Electromagnetic Compatibility - Requirements and Tests | |
| (Edition 2:2001 with Amendment 1:2004) | |
| IEC 62304:2006 | Medical device software - Software life cycle processes |
9
| Standard # and Date | Standard Title |
|---|---|
| IEC 60601-2-37:2007 | Medical electrical equipment - Part 2-37: Particular requirements for the basic |
| safety and essential performance of ultrasonic medical diagnostic and | |
| monitoring equipment. |
Summary of Clinical Testing 8.0
- 8.1 No clinical testing is required to be performed using SoftVue; however, image characterization testing using clinical data has been completed per study parameters suggested by the FDA during the Submission Issue Q-Sub Meeting (Q130909) held on August 23, 2013. The parameters are listed below.
-
10 - 20 patients
- A Range of breast densities from Fatty to Dense Breasts
- Small to Large Breasts A
- Lesion sizes 5 mm to 15 mm or 20 mm A
-
- 8.2 The study was conducted in order to demonstrate SoftVue's ability to provide qualitative tissue stiffness information with the color relative stiffness images. The invivo comparisons are not meant to guide a statistical study, but are solely intended to provide an illustrative example of in-vivo stiffness imaging using the modified SoftVue System.
- 8.3 As part of the evaluation, a phantom analysis was also included in the test protocol to establish a baseline for the clinical image evaluations. An anthropomorphic breast phantom was chosen for this initial analysis because its characteristics are predetermined such that the stiffness properties of the entire phantom and its inclusions are accurately known. The phantom contains stiff and soft inclusions of varying sizes. Each of the masses in the phantom have known stiffness characteristics that have been used to demonstrate that the color of the masses within the color stiffness images output by Soft Vue correlate to the stiffness of the masses within the anthropomorphic breast phantom. The appearance of each mass was used to qualitatively characterize the mass stiffness based on relative color differences.
- 8.3.1 The phantom scan yielded images of 7 inclusions. Among the 7 phantom inclusions, 1 cancer and 3 fibroadenomas were found to be stiff (appearing red) compared to the background material while the 3 cysts were found to be soft (appearing blue) in complete concordance with the known properties of the phantom.
- 8.4 Delphinus Medical Technologies conducted a small scale clinical study to collect clinical images from the modified Soft Vue system. The images collected include Bmode images as well as color and grayscale relative stiffness images. Patient data were collected as part of the clinical study that Delphinus currently has in process under pre-IED # I120143. A modified SoftVue system has been installed at the Alexander J Walt Breast Center at the Karmanos Cancer Institute located in Detroit, Michigan.
- 8.5 The image evaluations were conducted per protocol 100-00745, SoftVue Color Stiffness Image Characterization Protocol (Appendix 20-A).
10
- 8.6 The patient data were chosen from the clinical study on the basis of having a suspicion or a biopsy proven lesion such that the lesions in question could be identified by:
- 8.6.1 Appearance (echogenicity)
- 8.6.2 Size (dimensions)
- Location (clock position) 8.6.3
- All patient images from the SoftVue system were reviewed by board certified 8.7 radiologist, Dr. Peter Littrup. Previous biopsies and/or imaging were used to guide the identification of the lesions in the SoftVue images using clock position, appearance, size and location for guidance.
- 8.8 A set of 10 representative in-vivo comparisons of SoftVue's B-mode and color relative stiffness images was carried out to demonstrate SoftVue's ability to qualitatively measure tissue stiffness with clinical data, using the B-mode images for initial mass identification.
- A total of 10 SoftVue patient exams were used in the analysis. Some patients 8.8.1 had multiple lesions so that the final data set consisted of 13 imaged masses consisting of 4 cancers, 4 fibroadenomas, and 5 cysts.
- Breast cup size ranged from B to DDD with densities consisting of 5 scattered, 2 8.8.2 heterogeneous and 3 dense (one of which was extremely dense) indicating that a range of breast size and density was sampled.
- 8.9 All 4 cancers were characterized as "stiff" by SoftVue's color stiffness images. Two fibroadenomas were found to be mixed (range of colors), 1 was stiff (red) and 1 was found to be soft (blue). Of the 5 cysts, 4 were found to be soft, while 1 was found to be mixed. A summary of the results are included in Table 4 below.
| Mass
| Case
| Study # | Breas
t Size | Breast
Density | Lesion
Pathology | Reported
Lesion
Position | Average
Lesion
Size (cm) | Soft Vue
Appearance | SoftVue
Stiffness
Assessment |
|-----------|-----------|-------------|-----------------|--------------------|---------------------|--------------------------------|--------------------------------|---------------------------------------------------------------------------|------------------------------------|
| 1 | 1 | SV021 | C | Dense | Cancer | 8:00 | 2.5 | Hypoechoic
Red / green (redder
than background on
average) | Stiff |
| 2 | 2 | SV022 | DD | Scattered | Fibroadenoma | 1:30 | 3.0 | Hypoechoic
Yellow / green
(redder than
background on
average) | Stiff |
| 3 | 3 | SV045 | C | Scattered | Cancer | 10:00 | 1.8 | Hypoechoic
Red (redder than
background on
average) | Stiff |
| 4 | 4 | SV077_
1 | B | Extremely
Dense | Cyst | 2:00 | 1.4 | Anechoic
Blue/green (bluer
than background on
average) | Soft |
| 5 | 4 | SV077_
2 | B | Extremely
Dense | Cyst | 12:00 | 1.9 | Anechoic
Blue/green (bluer
than background on
average) | Soft |
Table 4: Clinical Image Analysis Summary
11
| Mass
| Case
| Study # | Breas
t Size | Breast
Density | Lesion
Pathology | Reported
Lesion
Position | Average
Lesion
Size (cm) | SoftVue
Appearance | SoftVue
Stiffness
Assessment |
|-----------|-----------|-------------|-----------------|--------------------|---------------------|--------------------------------|--------------------------------|------------------------------------------------------------------------|------------------------------------|
| 6 | 4 | SV077_
3 | B | Extremely
Dense | Cyst | 12:00 | 2.0 | Anechoic
Blue/green (bluer
than background on
average) | Soft |
| 7 | 5 | SV079 | C | Heterogene
ous | Cyst | 9:00 | 1.4 | Anechoic
Blue/green
(bluer than
background on
average) | Soft |
| 8 | 6 | SV089 | D | Scattered | Cancer | 9:30 | 1.7 | Hypoechoic
Red (redder than
background on
average) | Stiff |
| 9 | 7 | SV090 | DDD | 26yrs
(Hetero)* | Fibroadenoma | 10:00 | 4.3 | Hypoechoic
Blue/Green (range
of color, no
dominant color) | Mixed |
| 10 | 8 | SV113 | DD | Scattered | Cyst | 2:00 | 1.8 | Anechoic
Blue/green (range
of color, no
dominant color) | Mixed |
| 11 | 9 | SV114 | D | Scattered | Cancer | 10:00 RA | 1.2 | Hypoechoic
Red/green (redder
than background on
average) | Stiff |
| 12 | 10 | SV117_
1 | D | 21 yrs
(Dense)* | Fibroadenoma | 5:00 | 1.9 | Hypoechoic
Blue/green/red
(range of color, no
dominant color) | Mixed |
| 13 | 10 | SV117_
2 | D | 21 yrs
(Dense)* | Fibroadenoma | 8:00 | 2.6 | Hypoechoic
Blue (range of
color, no dominant
color) | Soft |
9.0 Conclusion
The modified SoftVue device performs as intended and is substantially equivalent to the unmodified SoftVue device with respect to intended use, design, principles of operation, technology, materials, and performance. Any noted differences do not raise any new issues of safety and effectiveness.